Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
复制标题
DOI：
10.1007/s11357-021-00471-6
复制
发表时间：
2021-10
期刊：
影响因子：
5.6
通讯作者：
Uher F
中科院分区：
文献类型：
--
作者：
Vályi-Nagy I;Matula Z;Gönczi M;Tasnády S;Bekő G;Réti M;Ajzner É;Uher F
本研究比较了BBIBP-corv(灭活病毒)疫苗和BNT162b2(信使核糖核酸)疫苗对SARS-CoV-2病毒的体液免疫和T细胞免疫应答。康复期志愿者也被调查，以评估活病毒诱导的获得性免疫。虽然两种疫苗都能诱导抗体和T细胞介导的免疫反应，但我们的分析揭示了这两类挑战之间在数量和质量上的显著差异。BBIBP-CorV疫苗可诱导健康人产生抗受体结合域抗体和抗刺蛋白(S)抗体，其水平明显低于BNT162b2疫苗接种后的水平，但仍高于恢复期患者。然而，注射BNT162b2的参与者累积的干扰素γ阳性T细胞反应仅比注射BBIBP-COV疫苗的参与者高两倍。此外，灭活病毒疫苗诱导的T细胞反应不仅针对S，还针对核衣壳(N)和膜(M)蛋白，而信使核糖核酸疫苗能够诱导更窄的反应，仅针对S蛋白表位。因此，BBIBP-Corv在未感染病毒的参与者中诱导的T细胞反应模式与在康复患者中观察到的细胞介导的抗SARS-CoV-2反应相似。根据这些数据，我们可以得出结论，BBIBP-Corv灭活疫苗是有效的免疫效果。然而，BBIBP-Corv诱导的整合、抗体和T细胞介导的免疫反应的持续时间需要进一步研究。网上版载有补充材料，可在10.1007/s11357.021-00471-6查阅。
In the present study, humoral and T cell-mediated immune responses elicited by BBIBP-CorV (inactivated virus) and BNT162b2 (mRNA-based) vaccines against SARS-CoV-2 virus were compared. Convalescent volunteers were also investigated to evaluate adaptive immunity induced by live virus. Although both vaccines induced antibody- and T cell-mediated immune responses, our analysis revealed significant quantitative and qualitative differences between the two types of challenges. The BBIBP-CorV vaccine elicited antireceptor-binding domain (RBD) IgG, as well as anti-spike protein (S) IgG and IgA antibodies in healthy individuals, the levels of which were much lower than after BNT162b2 vaccination but still higher than in the convalescent patients. The cumulative IFNγ-positive T cell response, however, was only twofold higher in participants injected with BNT162b2 compared to those who were primed and boosted with BBIBP-CorV vaccine. Moreover, the inactivated virus vaccine induced T cell response that targets not only the S but also the nucleocapsid (N) and membrane (M) proteins, whereas the mRNA vaccine was able to elicit a much narrower response that targets the S protein epitopes only. Thus, the pattern of BBIBP-CorV-induced T cell response in virus-naive participants was similar to the cell-mediated anti-SARS-CoV-2 response observed in convalescent patients. Based on these data, we can conclude that the BBIBP-CorV inactivated virus vaccine is immunologically effective. However, the duration of BBIBP-CorV-induced integrated, antibody, and T cell-mediated, immune responses needs further investigation. The online version contains supplementary material available at 10.1007/s11357-021-00471-6.
登录
查看更多内容
影响因子：
64.5
作者：
Sette A;Crotty S
通讯作者：
Crotty S
DOI：
10.1038/s41577-021-00522-1
发表时间：
2021-04
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
Carvalho T;Krammer F;Iwasaki A
通讯作者：
Iwasaki A
影响因子：
5.5
作者：
Zhang Y;Li D;Zhao H;Wang L;Liao Y;Li X;Mou T;Li Q
通讯作者：
Li Q
影响因子：
8.8
作者：
Dangi T;Class J;Palacio N;Richner JM;Penaloza MacMaster P
通讯作者：
Penaloza MacMaster P
灭活的SARS-COV-2疫苗的安全性和免疫原性，BBIBP-CORV：随机，双盲，安慰剂对照，1/2期试验。
DOI：
10.1016/s1473-3099(20)30831-8
发表时间：
2021-01
期刊：
The Lancet. Infectious diseases
影响因子：
--
作者：
Xia S;Zhang Y;Wang Y;Wang H;Yang Y;Gao GF;Tan W;Wu G;Xu M;Lou Z;Huang W;Xu W;Huang B;Wang H;Wang W;Zhang W;Li N;Xie Z;Ding L;You W;Zhao Y;Yang X;Liu Y;Wang Q;Huang L;Yang Y;Xu G;Luo B;Wang W;Liu P;Guo W;Yang X
通讯作者：
Yang X